158 related articles for article (PubMed ID: 30216639)
1. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
Ding M; Zollinger W; Ebeling R; Heard D; Posey R
J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639
[TBL] [Abstract][Full Text] [Related]
2. A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.
Henderson MA; Hoopes DJ; Fletcher JW; Lin PF; Tann M; Yiannoutsos CT; Williams MD; Fakiris AJ; McGarry RC; Timmerman RD
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):789-95. PubMed ID: 19473777
[TBL] [Abstract][Full Text] [Related]
3. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
5. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18F-fluorodeoxyglucose positron emission tomography/computed tomography serial tumor response assessment.
Vahdat S; Oermann EK; Collins SP; Yu X; Abedalthagafi M; Debrito P; Suy S; Yousefi S; Gutierrez CJ; Chang T; Banovac F; Anderson ED; Esposito G; Collins BT
J Hematol Oncol; 2010 Feb; 3():6. PubMed ID: 20132557
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.
Dunlap NE; Yang W; McIntosh A; Sheng K; Benedict SH; Read PW; Larner JM
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1071-7. PubMed ID: 22898383
[TBL] [Abstract][Full Text] [Related]
8. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
9. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
Lu JY; Lin PX; Huang BT
Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
Horne ZD; Clump DA; Vargo JA; Shah S; Beriwal S; Burton SA; Quinn AE; Schuchert MJ; Landreneau RJ; Christie NA; Luketich JD; Heron DE
Radiat Oncol; 2014 Jan; 9():41. PubMed ID: 24479954
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A
Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749
[TBL] [Abstract][Full Text] [Related]
12. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.
Na F; Wang J; Li C; Deng L; Xue J; Lu Y
J Thorac Oncol; 2014 Jun; 9(6):834-42. PubMed ID: 24787963
[TBL] [Abstract][Full Text] [Related]
13. Use of FDG-PET to guide dose prescription heterogeneity in stereotactic body radiation therapy for lung cancers with volumetric modulated arc therapy: a feasibility study.
de Figueiredo BH; Antoine M; Trouette R; Lagarde P; Petit A; Lamare F; Hatt M; Fernandez P
Radiat Oncol; 2014 Dec; 9():300. PubMed ID: 25534014
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Tanaka H; Hayashi S; Hoshi H
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
[TBL] [Abstract][Full Text] [Related]
15. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
16. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
Hong R; Halama J; Bova D; Sethi A; Emami B
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
[TBL] [Abstract][Full Text] [Related]
17. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
18. Defining target volumes for stereotactic ablative radiotherapy of early-stage lung tumours: a comparison of three-dimensional 18F-fluorodeoxyglucose positron emission tomography and four-dimensional computed tomography.
Hanna GG; van Sörnsen de Koste JR; Dahele MR; Carson KJ; Haasbeek CJ; Migchielsen R; Hounsell AR; Senan S
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):e71-80. PubMed ID: 22445302
[TBL] [Abstract][Full Text] [Related]
19. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
[TBL] [Abstract][Full Text] [Related]
20. Individualized Fraction Regimen of SBRT Patients With Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-Free Control Probability.
Feng AH; Wang H; Chen H; Gu HL; Shao Y; Duan YH; Huang Y; Fu XL; Zhou T; Xu ZY
Technol Cancer Res Treat; 2021; 20():15330338211011967. PubMed ID: 33982619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]